Integra LifeSciences Holdings Corporation

Integra LifeSciences Holdings Corporation

IARTNYSE / NASDAQHealthcareSmall cap

$13.25-$0.30 (-2.2%)

Last close · Data as of Nov 20, 2026

Market cap
$1.4B
P/E
-2.6x
EV / EBITDA
-9.7x
Revenue
$1.6B
Net margin
-31.6%
ROCE
0.6%

+19.9% over the last year

Integra LifeSciences Holdings Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-0.6%
3M
-20.1%
6M
-13.9%
1Y
+19.9%
5Y
-80.8%

52-week range

Day change -$0.30 (-2.2%) from $14 to $13 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in IART, bought on each weekday since 2021.

News & filings

What Integra LifeSciences Holdings filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 516 million US dollars in fiscal 2025.

Strengths (1)

  • Current assets are 2.54 times current liabilities.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments.

Read moreShow less

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical, ear, nose, throat, and wound care products for use in neurosurgery, neurocritical care, and otolaryngology. It operates through Codman Specialty Surgical and Tissue Technologies segments. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment. It also offers after-market services; surgical headlamps and instrumentation; instrument patterns and surgical and lighting products to hospitals, surgery centers, dental, podiatry, and veterinary offices. In addition, the company provides treatment of acute wounds, such as burns; chronic wounds, including diabetic foot ulcers; and surgical tissue repair applications, including hernia reinforcement, tendon protection, and peripheral nerve repair. Further, it offers skin and wound repair, plastics and surgical reconstruction products, and nerve and tendon repair products. Additionally, the company is involved in the ear, nose, and throat business that includes instrumentation, balloon technologies for sinus dilation and eustachian tube dilation, and surgical navigation systems. It offers its products directly through various salesforces and other distribution channels to the hospitals, integrated health networks, group purchasing organizations, clinicians, surgery centers, and health care providers in the United States, Europe, the Asia Pacific, and internationally. Integra LifeSciences Holdings Corporation was formerly known as Integra LifeSciences Corp. and changed its name to Integra LifeSciences Holdings Corporation in June 1995. Integra LifeSciences Holdings Corporation was incorporated in 1989 and is headquartered in Princeton, New Jersey.

Sector
Healthcare
Shares outstanding
77.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.4B
P/E
-2.6x
P/B
1.3x
EV / EBITDA
-9.7x
EV / Sales
1.9x
P/S
0.8x
52-week high
$19.85
52-week low
$8.90

Profitability

Operating margin
1.1%
Net margin
-31.6%
EBITDA margin
-19.9%
ROE
-49.5%
ROCE
0.6%
ROA
-14.3%
Asset turnover
0.45

Growth

Revenue
$1.6B
Revenue growth, 1Y
1.5%
Revenue CAGR, 3Y
1.6%
Net profit growth, 1Y
7337.7%
Free cash flow
-$45.3M

Solvency

Current ratio
2.54
Debt / Equity
1.95
Debt / Assets
0.56
CFO / Net profit
-0.10
Cash / Market cap
17.2%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$1.6B
Cost of revenue$803.6M
Gross profit$831.6M
Operating expenses$813.6M
Research and development$99.0M
Selling, general and administrative$699.7M
Operating income$18.0M
Interest and other-$581.5M
Pretax income-$563.5M
Tax and other-$47.0M
Net income-$516.5M

Revenue and net profit

Revenue grew 1.5% in FY2025; net profit is the dashed line.

Integra LifeSciences Holdings Corporation revenue and net profit by fiscal year
Integra LifeSciences Holdings Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$1.6B$180.6M
FY2023$1.5B$67.7M
FY2024$1.6B-$6.9M
FY2025$1.6B-$516.5M

Cash flows

FY2025: $50.4M from operations, -$45.3M free after investment (dashed).

Integra LifeSciences Holdings Corporation operating and free cash flow by fiscal year
Integra LifeSciences Holdings Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$264.5M$217.4M
FY2023$140.0M$73.1M
FY2024$129.4M$15.0M
FY2025$50.4M-$45.3M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$1.6B+1.5%1Y
EBITDA
-$325.4M-268.4%1Y
Net profit
-$516.5M
Cash from operations
$50.4M-61.1%1Y
Free cash flow
-$45.3M-401.5%1Y
Revenue CAGR, 3Y
1.6%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$1.6B-$325.4M-$516.5M-$45.3M-49.5%+1.5%+7337.7%

Monthly returns

Month-by-month returns of IART across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$3.6B
Liabilities$2.6B
Equity$1.0B
Paid-in capital$1.3B
Retained earnings$423.4M
Treasury stock$689.2M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; IART highlighted.

P/E against peers

Most of this group is loss-making, so EV / Sales is compared for the companies without a P/E.

No company in this group has a positive P/E.

EV / Sales, for the companies without earnings

  1. Integra LifeSciences Holdings Corporation (this company)1.9x

Not shown (no positive earnings and no EV / Sales): MapLight Therapeutics, Inc., Bicara Therapeutics Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
Integra LifeSciences Holdings CorporationIARTthis company$1.4B-2.6x1.3x-49.5%-9.7x
AtriCure, Inc.ATRC$1.4B-120.6x2.8x-2.3%79.2x
Precigen, Inc.PGEN$1.4B-5.5x65.8x-1198.6%-5.9x
MapLight Therapeutics, Inc.MPLT$1.4B—3.0x-35.2%—
Butterfly Network, Inc.BFLY$1.4B—6.9x-39.3%—
UroGen Pharma Ltd.URGN$1.3B-8.8x-12.7x145.5%-10.0x
Bicara Therapeutics Inc.BCAX$1.3B-9.7x3.3x-34.4%-8.0x
Inhibrx Biosciences, Inc.INBX$1.3B-9.6x167.5x-1752.2%-10.5x
Ardelyx, Inc.ARDX$1.3B-21.7x8.0x-36.9%-50.5x
Peer median—-9.6x5.1x-36.0%-9.0x

Year-to-date ROI

IART since 1 January, against earlier years.

Historical volatility

IART's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

Integra LifeSciences Holdings Corporation operating margin by fiscal year
Integra LifeSciences Holdings Corporation operating margin by fiscal year
DateOperating margin
FY202215.3%
FY20237.2%
FY20241.8%
FY20251.1%
LineFY2025
Cost of revenueCost Of Revenue$803.6M
Gross profitGross Profit$831.6M
Operating expensesOperating Expense$813.6M
Research and developmentResearch And Development$99.0M
Selling, general and administrativeSelling General And Administration$699.7M
Depreciation and amortisationDepreciation And Amortization In Income Statement$14.9M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$14.9M
Amortization$14.9M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$14.9M
Total expensesTotal Expenses$1.6B
Pretax incomePretax Income-$563.5M

Learn while you research

Academy chapters picked for Integra LifeSciences Holdings Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Leverage RatiosDebt/Equity of 1.95 is elevated, understand what that means for solvency.6 min read
  3. 03 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  4. 04 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  5. 05 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  6. 06 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →